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Abstract
Background: Medium-chain triacylglycerols (MCT), omega-3 polyunsaturated fatty acids (n-3-PUFA) and
micronutrients may be useful for weight and cardiometabolic risk management. However, studies analyzing the
effect of a combination of both in individuals at increased cardiometabolic risk are lacking. Therefore, this
randomized, controlled, double-blind study investigated the effect of a fat spread enriched with two different
doses of MCT and a special long-chain fatty acid-micronutrient combination on cardiometabolic risk factors in
overweight diabetic patients.
Methods: Fifty-four patients received either a fat spread with 6 g/d MCT (MCT30%) or 1.2 g/d (MCT6%). Forty-three
completed the study. Analysis was performed according to the median of MCT intake (supplemented and food-
derived MCT). Clinical, anthropometric, blood, 24 h-urine parameters and dietary intake were assessed at baseline
and after 12 weeks.
Results: Total MCT intake > 7 g/d (MCT > 7 group) significantly reduced waist circumference (WC) by 1.81 ± 2.69
cm, whereas ≤ 7 g/d MCT (MCT ≤ 7 group) increased WC by 0.32 ± 3.03 cm (p = 0.027), which was supported by
a change in waist-to-height ratio (WHtR) (p = 0.018). Fasting serum triglycerides (TG) increased in both groups over
time due to dietary habits. In contrast, diabetic metabolic situation and urinary albumin excretion did not alter.
Urinary pH differed significantly between groups after 12 weeks.
Conclusion: An intake of >7 g/d MCT reduced WC in overweight diabetics, whereas the increase in the intake of
fatty acids may have worsened fasting TG. Therefore, the suitability of a fat for nutrient enrichment remains to be
challenged, and further studies in low-fat matrices are desirable.
Introduction
Evidence indicates the importance of abdominal adipose
tissue as endocrine tissue being key for cardiometabolic
risk factors [1]. Among patients with type 2 diabetes the
combination of abdominal enlargement and hypertriglycer-
idemia, so-called hypertriglyceridemic waist (HW), is highly
prevalent [2] and has been associated with a greater degree
of subclinical atherosclerosis that may be related to the
proatherogenic lipoprotein changes [3,4]. These lipoprotein
changes called atherogenic dyslipidemia are typically char-
acterized by reduced concentrations of HDL cholesterol
(HDL-C), elevated triglycerides (TG), and elevated small,
dense LDL particles [5]. HW has also been proposed to be
an important factor increasing C-reactive protein (CRP)
concentrations and relative coronary risk in patients with
type 2 diabetes of any age and sex [6,7]. Moreover, reactive
oxygen species are produced in various tissues under dia-
betic conditions leading to an antioxidant depletion and * Correspondence: christine.metzner@rwth-aachen.de
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(AGE), cell damage and endothelial dysfunction [8,9].
A supplementation of medium-chain triacylglycerols
(MCT) for conventional dietary fats has been proposed
as beneficial for weight management, since MCT are
rapidly absorbed and preferentially transported through
the portal venous system to the liver. The subsequent
stimulation of b-oxidation in hepatocytes may reduce
the circulating fatty acids available to the adipocytes
[10]. Moreover, MCT enhances energy expenditure fol-
lowing thermogenesis [11-13].
The cardiometabolic protective effects of omega-3
polyunsaturated fatty acids (n-3-PUFA) appear to be due
to a synergism between multiple mechanisms. These
involve anti-inflammatory, inflammation-resolving,
anti-arrhythmic and anti-thrombotic effects as well as
a regulation of transcription factors, gene expression
and membrane fluidity [14]. Moreover, n-3-PUFA, in
particular eicosapentaenoic acid (EPA) and docosahex-
aenoic acid (DHA), have been demonstrated to exert
beneficial effects in lowering TG concentrations [15],
including in patients with atherogenic dyslipidemia
associated diabetes [16,17].
Since the fat spreads were also enriched with vitamins
and minerals, their consumption may add to an increase
in the daily supply of these essential micronutrients, and
thus ameliorate nutritional status. These changes may
exert favourable effects on weight management and car-
diometabolic risk factors [18,19].
As fat spread is a central source of fat in the diet, the
choice of a spread providing a high-quality fat and
micronutrient profile may be an important dietary mea-
sure for patients with diabetes. Fat spreads characterized
by a combination of MCT, n-3-PUFA and micronutri-
ents have not been evaluated so far in this cohort.
Therefore, aim of this study was to assess the benefit of
a fat spread characterized by the above mentioned com-




Overweight diabetic patients were recruited from the
region of Altomuenster, Bavaria, Germany. Both men
and women aged 30 to 82 years with a body mass index
(BMI) of 27 kg/m
2 or greater and a waist circumference
(WC) ≥94 cm for women and ≥102 cm for men were
included into the study. Overweight diabetic patients
were defined by clinical criteria. Individuals taking any
medication or nutritional supplements for weight reduc-
tion were excluded. Further exclusion criteria comprised
the supplementation and/or therapy with marine n-3-
PUFA, micronutrients, treatment with glitazones and/or
telmisartan, insulin-dependent diabetes, ketoacidosis and
acute or chronic diarrhea. The study was approved by
the Ethics Committee of the Bavarian Chamber of Phy-
sicians, Munich, Germany, and all patients provided
informed consent before study onset.
Study design
This prospective study was carried out in a double-blind
controlled manner. Patients were randomly assigned to
receive a fat spread with either 6 g/d (MCT30%) or
1.2 g/d MCT (MCT6%), which were equally enriched
with special unsaturated fatty acids and micronutrients
(Table 1). Patients were asked to consume 2 × 15 g/d of
the fat spreads (MCT30% or MCT6%, respectively) for
12 weeks as substitution for their usual dietary spread
Table 1 Mean composition of the MCT30% and MCT6%
fat spread per daily serving (2 × 15 g)
1
MCT30% MCT6%
Energy (kcal) 176 176
Carbohydrates (g) 0 0
Protein (g) 0 0
Fat (g) 19.5 19.5
Fatty acids
SAFA (g) 8.7 7.2
- MCT (g) 6.0 1.2
- SAFA without MCT (g) 2.7 6.0
MUFA (g) 6.9 8.1
- Oleic acid (g) 6.6 7.8
PUFA (g) 3.9 4.2
- LA (g) 2.88 3.1
- ALA (g) 0.87 0.9
- EPA (g) 0.15 0.15
- DHA (g) 0.09 0.09
Trans fatty acids (g) 0.12 0.09
Cholesterol (g) 0.006 0.006
Micronutrients
Vitamin A (μg RE) 240 240
Vitamin B1(mg) 0.45 0.45
Vitamin B2 (mg) 0.48 0.48
Nicotinic acid (mg) 4.95 4.95
Vitamin B6 (mg) 0.48 0.48
Folic acid (μg) 120 120
Vitamin B12 (μg) 1.95 1.95
Vitamin D3 (μg) 1.8 1.8
Vitamin E (mg) 3.3 3.3
Sodium (g) 0.002 0.002
Chrome (mg) 0.015 0.015
Manganese (mg) 0.6 0.6
1 abbreviations used: ALA, alpha-linolenic acid; EPA, eicosapentaenoic acid;
DHA, docosahexaenoic acid; LA, linolenic acid; MCT, medium-chain
triacylglycerols; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated
fatty acids; RE, retinol equivalent; SAFA, saturated fatty acids.
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level during the study.
Data were analyzed at baseline and 12 weeks of inter-
vention. Body weight (kg), height (cm) and WC (cm)
were measured. WC was determined to the nearest
0.1 via flexible tape and measurement was documented
by photography. Anthropometric measurements and
venous blood samples were performed in the morning
after an overnight fasting period of at least 12 h. Dietary
intake data (3-day food record) was analyzed using
PRODI 5.5 software (WVG, Stuttgart, Germany). The
average of three days was assessed. Glomerular filtration
rate (GFR) was calculated using the Modification of Diet
in Renal Disease (MDRD) study equation [20]. Compli-
ance was monitored by weighing of returned spread
tubs at week 8 and 12 of intervention as well as by eval-
uating dietary records on which the number of spread
servings per day were recorded. Analysis was performed
according to the median of MCT intake (supplemented
and food-derived MCT), which was 7 g/d MCT.
Laboratory methods
SYSCOMP GmbH, Augsburg, Germany, conducted all
laboratory analyses. Analysis of serum glucose (hexoki-
nase method), uric acid (uricase-PAP method), gamma-
glutamyltransferase (GGT), aspartate-aminotransferase
(ASAT), alanine-aminotransferase (ALAT) (IFCC
method), glycated haemoglobin (HbA1c) (turbidimetric
immunologic inhibition assay (TINIA)), insulin (ECLIA),
total cholesterol (TC) (CHOD-PAP method), LDL-C
and HDL-C (enzymatic colour test), TG (GPO-PAP
method), CRP sensitive (turbidimetry) and 24 h urinary
albumin (turbidimetry), pH (Combur test) and sodium
(ion sensitive electrode (ISE)) were measured on Roche
analyser.
Statistical methods
All data are presented as means ± standard deviation.
Significance was set at p-value 0.05 (two-sided). Changes
of WC and body weight from baseline were determined
using non-parametric analyses (exact Mann-Whitney-U-
test). Pre-post intervention changes of all other variables
were analyzed via non-parametric Wilcoxon test and
inter-group differences were compared using Mann-
Whitney-U test. ANCOVA including use of WC change
as a covariate was used to control for the potential con-
founder of serum fasting TG. Data analysis was per-
formed based on the per protocol population and by
using SPSS
® for Windows (version PASW 18.0).
Results
Participants
A total of 54 overweight diabetic patients were
recruited, of whom 43 were included into the per
protocol (PP) population (23 men and 20 women).
Reasons for an exclusion from the PP population
included poor compliance as determined by more than
20% variance of product consumption (n = 7) and varia-
tion in study duration of more than 7 days (n = 2).
Moreover, 2 patients left the study due to personal rea-
sons (additional file 1). Both fat spreads were well toler-
ated by the patients and the majority of patients
followed the treatment without any reported difficulty.
Male and female subjects were equally distributed (12
and 9 in the MCT > 7 group, 11 and 11 in the MCT ≤
7 group, respectively; p = 0.639). Metformin was used as
anti-diabetic medication by 20 and sulfonylurea by 13
patients. Statins were taken as cholesterol-lowering
medication by 11 and antihypertensive medication
(beta-blocker, angiotensin converting enzyme inhibitors
and calcium channel blocker) by 49 patients.
Clinical measurements
A total MCT intake > 7 g/d (n = 21) significantly
reduced WC by 1.81 ± 2.69 cm (p = 0.005), whereas no
significant change was observed in the MCT ≤ 7g r o u p
(n = 22) (0.32 ± 3.03 cm, p = 1.000) over time (Table
2). The inter-group changes differed significantly (p =
0.027). Additionally, a significant difference in waist-to-
height ratio (WHtR) was observed between groups (p =
0.018), whereas BMI and body weight changes did not
change significantly. Systolic and diastolic blood pres-
sure remained unaffected by the supplementation in
both groups.
Serum parameters
The average value of fasting TG was below the cut-off level
of 150 mg/dL in the MCT > 7 group (147.3 ± 92.0 mg/dL),
whereas the fasting triglyceride level of the MCT ≤ 7g r o u p
was hypertriglyceridemic (166.5 ± 113.3 mg/dL) (Table 2).
Over time, fasting TG increased significantly in both
groups (p = 0.021 and p = 0.022, respectively), but there
was no inter-group difference. Total cholesterol (TC),
LDL-C, HDL-C, non-HDL-C and TC/HDL-C ratio did
not change during supplementation. Fasting glucose,
insulin, HOMA index, HbA1c and CRP were elevated in
both groups during the study, but were not affected by
intervention. The same applies to ASAT and ALAT,
however GGT increased significantly in the MCT ≤ 7
group (p = 0.023). In the MCT > 7 group, uric acid
increased significantly during supplementation (p =
0.024), but remained within the normal range.
Urine parameters
Whereas no changes were observed for GFR, urinary
albumin and sodium excretion, urinary pH varied signif-
icantly between groups after 12 weeks of intervention
(p = 0.032) (Table 2).
Siener et al. Nutrition & Metabolism 2011, 8:21
http://www.nutritionandmetabolism.com/content/8/1/21
Page 3 of 8Dietary intake
Except for the MCT intake, there was no significant dif-
ference in macro- and micronutrient consumption
between both groups (Table 3). However, the relation of
macronutrients shifted due to changes in dietary habits.
Fat intake and percentage of energy consumed from fat
increased during supplementation, however this change
was not significant in the MCT > 7 group. Saturated fat
intake was found to be significantly elevated in the
MCT > 7 group by 7.3 ± 11.7 g/d (p = 0.016), mainly
due to supplementation. PUFA consumption increased
significantly only in the MCT > 7 group (p = 0.033),
whereas monounsaturated fatty acid (MUFA) intake,
including oleic acid, was significantly higher following
fat spread consumption in both groups (p < 0.039 and
0.010, respectively). The same applied for daily alpha-
linolenic acid (ALA), EPA and DHA intake. Glucose,
fructose, sorbitol and purine intake remained stable over
time. However, the fat spread consumption affected
daily vitamin supply, as revealed by a significant increase
in vitamin D, B2 and folic acid intake after 12 weeks in
both groups. Vitamin E intake rose in the MCT > 7
group, and nicotinic acid as well as vitamin B6 con-
sumption were significantly enhanced over time in the
MCT ≤ 7 group, without significant differences between
groups.
Discussion
To our knowledge this is the first study investigating the
effect of a fat spread enriched with MCT and a special
fatty acid-micronutrient combination on cardiometabolic
risk factors in overweight diabetic patients. The major
finding of the present study was a significant decrease in
WC in the MCT > 7 group. The reduction in WC
Table 2 Clinical and biochemical characteristics at baseline and after supplementation
1,2
MCT intake > 7 g/d (n = 21) MCT intake ≤ 7 g/d (n = 22) P
b
wk 0 wk 12 wk 12 - 0 P
a wk 0 wk12 wk 12 - 0 P
a
Age (years) 67.3 ± 9.3 66.3 ± 7.2 0.512
Weight (kg) 95.7 ± 21.2 95.3 ± 21.7 -0.35 ± 1.92 0.641 87.7 ± 11.6 88.3 ± 11.7 0.54 ± 1.76 0.118 0.177
BMI (kg/m
2) 34.35 ± 6.84 34.23 ± 7.08 -0.12 ± 0.70 0.681 31.69 ± 4.05 31.89 ± 4.10 0.20 ± 0.61 0.092 0.174
WC (cm) 112.5 ± 12.5 110.7 ± 12.9 -1.81 ± 2.69 0.005 106.4 ± 6.6 106.7 ± 7.0 0.32 ± 3.03 1.000 0.027
WHtR 0.676 ± 0.076 0.665 ± 0.079 -0.010 ± 0.016 0.008 0.640 ± 0.045 0.642 ± 0.049 0.002 ± 0.018 0.920 0.018
SBP (mmHg) 138.6 ± 18.4 137.9 ± 12.0 -0.7 ± 13.2 0.792 148.4 ± 18.6 142.0 ± 17.2 -6.4 ± 15.4 0.069 0.249
DBP (mmHg) 84.8 ± 11.7 84.1 ± 7.7 -0.7 ± 10.3 0.707 87.7 ± 8.7 85.2 ± 8.7 -2.5 ± 9.2 0.170 0.612
Fasting TG (mg/dl) 147.3 ± 92.0 181.6 ± 122.7 34.2 ± 72.6 0.021 166.5 ± 113.3 216.6 ± 177.1 50.1 ± 108.1 0.022 0.990
TC (mg/dl) 209.5 ± 41.0 214.0 ± 41.6 4.52 ± 18.60 0.177 217.7 ± 37.9 225.4 ± 42.7 7.68 ± 23.04 0.058 0.527
LDL-C (mg/dl) 128.8 ± 34.9 130.7 ± 32.3 1.95 ± 16.59 0.357 136.4 ± 34.9 135.6 ± 40.1 -0.86 ± 22.04 0.848 0.618
HDL-C (mg/dl) 52.1 ± 10.8 49.7 ± 10.6 -2.39 ± 8.75 0.230 49.5 ± 9.9 51.4 ± 13.9 1.88 ± 6.71 0.363 0.085
TC/HDL-C 4.15 ± 0.98 4.50 ± 1.37 0.35 ± 0.82 0.064 4.51 ± 1.01 4.65 ± 1.50 0.14 ± 0.70 0.637 0.289
Non-HDL-C (mg/dl) 157.4 ± 40.3 164.3 ± 43.5 6.91 ± 18.8 0.058 168.2 ± 35.6 174.0 ± 42.8 5.80 ± 22.7 0.158 0.981
Fasting glucose (mg/dl) 127.5 ± 21.8 132.0 ± 29.7 4.48 ± 19.91 0.422 124.4 ± 23.9 126.5 ± 34.6 2.09 ± 18.70 0.676 0.313
Fasting insulin (μU/ml) 12.6 ± 9.1 13.7 ± 11.0 1.09 ± 9.33 0.509 14.4 ± 6.8 17.6 ± 25.4 3.17 ± 24.16 0.299 0.177
HOMA-Index 4.14 ± 3.73 4.81 ± 5.52 0.68 ± 5.21 0.639 4.46 ± 2.39 5.72 ± 9.01 1.26 ± 8.68 0.306 0.234
HbA1c (%) 6.76 ± 0.58 6.69 ± 0.78 -0.067 ± 0.380 0.367 6.46 ± 0.47 6.46 ± 0.53 0.004 ± 0.208 0.844 0.179
CRP (mg/l) 6.17 ± 5.97 5.52 ± 4.91 -0.66 ± 2.77 0.140 5.80 ± 8.46 4.45 ± 4.63 -1.35 ± 6.76 0.274 0.961
Uric acid (mg/l) 5.96 ± 1.53 6.27 ± 1.52 0.31 ± 0.66 0.024 6.58 ± 1.26 6.58 ± 1.04 0.00 ± 1.09 0.944 0.103
GGT (U/l) 43.8 ± 50.1 41.2 ± 26.4 -2.57 ± 27.84 0.265 43.8 ± 47.6 44.2 ± 30.5 0.45 ± 20.82 0.023 0.442
ASAT (U/l) 28.4 ± 10.6 28.0 ± 8.3 -0.43 ± 5.97 0.861 28.1 ± 11.9 27.1 ± 6.5 -1.00 ± 9.01 0.480 0.643
ALAT (U/l) 33.5 ± 21.8 31.2 ± 14.3 -2.24 ± 9.96 0.650 29.2 ± 14.1 30.4 ± 13.8 1.18 ± 10.77 0.166 0.607
GFR (mL/min/1.73 m
2) 87.9 ± 19.1 86.4 ± 22.4 -1.54 ± 11.28 0.433 81.7 ± 15.7 83.4 ± 14.9 1.71 ± 8.60 0.095 0.290
U-Albumin (mg/24 h) 55.3 ± 199.4 19.5 ± 39.9 -35.8 ± 162.7 0.594 62.1 ± 225.8 60.0 ± 150.1 -2.1 ± 109.3 0.641 0.842
U-pH (24 h) 5.81 ± 0.81 5.52 ± 0.73 -0.29 ± 0.70 0.062 5.80 ± 1.08 6.05 ± 1.12 0.25 ± 0.88 0.176 0.032
U-Sodium (mmol/24 h) 212.0 ± 84.6 234.5 ± 89.0 22.5 ± 78.2 0.145 208.6 ± 67.6 231.0 ± 75.6 22.4 ± 72.2 0.153 1.000
1 data are presented as mean ± SD.
a p values for comparison between week 0 and 12 (Wilcoxon-Test).
b p value for comparison of group × time interactions (Mann-Whitney-U-Test).
2 abbreviations used: ASAT, aspartate-aminotransferase; ALAT, alanine-aminotransferase; CRP, C reactive protein; DBP, diastolic blood pressure; GFR, glomerular
filtration rate; GGT, gamma-glutamyltransferase; HbA1c, glycated haemoglobin; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; MCT, medium-chain
triacylglycerols; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides; WC, waist circumference; WHtR, waist to height ratio; U-albumin, urinary
albumin; U-pH, urinary pH; U-sodium, urinary sodium.
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research evaluating the effect of MCT in overweight sub-
jects [21-23]. The supplementation of 5 g/d MCT in form
of an oil for instance resulted in a significant decrease in
WC compared to the long-chain triacylglycerols (LCT)
control treatment (-5.1 ± 3.1 cm vs. -3.3 ± 1.9 cm, p <
0.05) [21]. Tsuji et al. [23] reported a significant reduction
in WC by 5.67 ± 0.05 cm with BMI ≥ 23 kg/m
2, however
only in the area of subcutaneous fat, at a total daily MCT
intake of 9.24 g/d.
Table 3 Daily dietary intake at baseline and after supplementation
1,2
MCT intake > 7 g/d (n = 21) MTC intake ≤7 g/d (n = 22) P
b
wk 0 wk 12 wk 12 - 0 P
a w k0 w k1 2 w k1 2-0 P
a
Energy (kcal/d) 2341.9 ± 650.0 2440.4 ±
758.4
98.5 ± 601.3 0.566 2234.4 ± 950.3 2518.8 ±
1095.4
284.5 ± 1229.6 0.223 0.593
Protein (g/d) 95.6 ± 22.7 93.4 ± 40.7 -2.2 ± 37.9 0.498 90.6 ± 45.7 102.7 ± 57.6 12.1 ± 67.3 0.263 0.211
Protein (%EN) 16.89 ± 2.23 15.43 ± 2.90 -1.47 ± 2.92 0.027 16.27 ± 3.10 16.13 ± 2.72 -0.14 ± 3.55 0.592 0.198
Carbohydrates (g/d) 237.0 ± 59.3 237.2 ± 62.3 0.2 ± 58.1 0.931 240.9 ± 96.9 241.1 ± 86.0 0.2 ± 109.3 0.808 0.771
Carbohydrates (%EN) 41.42 ± 6.35 40.53 ± 7.14 -0.89 ± 5.83 0.715 44.79 ± 7.74 40.27 ± 7.65 -4.51 ± 7.53 0.014 0.076
Fat (g/d) 93.4 ± 30.4 106.6 ± 37.6 13.2 ± 30.2 0.068 89.1 ± 47.0 111.0 ± 57.6 21.9 ± 60.5 0.050 0.789
Fat (%EN) 36.4 ± 5.5 39.4 ± 4.7 3.03 ± 6.16 0.079 35.1 ± 6.2 39.1 ± 5.8 4.04 ± 6.04 0.006 0.423
Alcohol (g/d) 21.3 ± 35.4 19.3 ± 28.2 -1.96 ± 16.86 0.476 11.8 ± 20.2 17.9 ± 27.6 6.03 ± 24.84 0.227 0.206
Alcohol (%EN) 5.33 ± 7.61 4.66 ± 6.29 -0.67 ± 3.29 0.590 3.86 ± 6.05 4.48 ± 6.58 0.62 ± 5.65 0.872 0.771
Cholesterol (mg/d) 363.2 ± 145.2 393.6 ± 213.7 30.4 ± 160.4 0.543 332.4 ± 189.0 359.7 ± 193.7 27.2 ± 259.2 0.758 0.884
SAFA (g/d) 34.6 ± 13.9 41.9 ± 13.5 7.3 ± 11.7 0.016 32.4 ± 17.7 40.2 ± 18.8 7.8 ± 21.1 0.072 0.942
MCT (g/d) 1.31 ± 0.76 7.74 ± 0.56 6.43 ± 0.83 <0.001 1.08 ± 0.64 4.94 ± 2.12 3.86 ± 2.29 <0.001 <0.001
MUFA (g/d) 34.0 ± 12.3 39.9 ± 16.0 5.9 ± 13.5 0.039 34.1 ± 19.9 45.5 ± 26.5 11.3 ± 27.1 0.010 0.627
PUFA (g/d) 14.5 ± 6.6 16.8 ± 5.7 2.3 ± 6.6 0.033 14.7 ± 7.7 18.2 ± 9.0 3.4 ± 9.5 0.082 0.981
Oleic acid (g/d) 30.1 ± 11.2 35.8 ± 14.4 5.7 ± 12.5 0.039 30.1 ± 17.7 40.7 ± 24.5 10.7 ± 24.6 0.011 0.610
LA (g/d) 12.34 ± 5.76 13.79 ± 4.98 1.45 ± 5.61 0.073 12.91 ± 6.88 15.21 ± 8.09 2.30 ± 8.30 0.322 0.981
ALA (g/d) 1.35 ± 0.82 2.09 ± 0.38 0.74 ± 0.78 0.001 1.15 ± 0.54 2.03 ± 0.66 0.88 ± 0.79 <0.001 0.409
LA/ALA 9.60 ± 1.87 6.47 ± 1.23 -3.14 ± 2.08 <0.001 11.37 ± 3.70 7.22 ± 1.70 -4.15 ± 3.43 <0.001 0.395
EPA (g/d) 0.040 ± 0.038 0.187 ± 0.035 0.147 ± 0.048 <0.001 0.035 ± 0.039 0.178 ± 0.027 0.143 ± 0.049 <0.001 0.981
DHA (g/d) 0.075 ± 0.085 0.192 ± 0.148 0.117 ± 0.167 0.003 0.068 ± 0.116 0.152 ± 0.071 0.083 ± 0.151 0.001 0.752
LA/(ALA+EPA+DHA) 8.72 ± 1.63 5.50 ± 1.11 -3.22 ± 1,65 <0.001 10.56 ± 3.67 6.20 ± 1.57 -4.35 ± 3.35 <0.001 0.296
Glucose (g/d) 11.4 ± 6.4 13.7 ± 6.1 2.3 ± 7.0 0.106 14.7 ± 7.4 13.7 ± 8.9 -1.0 ± 8.8 0.661 0.174
Fructose (g/d) 16.7 ± 10.4 17.7 ± 8.8 1.0 ± 11.6 0.532 20.2 ± 9.3 18.0 ± 11.1 -2.1 ± 12.2 0.527 0.296
Sorbitol (g/d) 1.01 ± 0.83 1.25 ± 1.12 0.24 ± 1.37 0.498 1.01 ± 0.58 1.70 ± 1.46 0.69 ± 1.49 0.051 0.437








1845.3 ± 792.9 -766.5 ±
3442.7
0.783 0.789
Vitamin D (μg/d) 3.09 ± 3.68 5.54 ± 4.76 2.45 ± 6.08 0.010 2.48 ± 3.58 3.54 ± 2.01 1.06 ± 4.36 0.042 0.627
Vitamin E (mg/d) 11.01 ± 5.25 14.45 ± 4.25 3.44 ± 4.66 0.004 12.10 ± 5.65 15.03 ± 7.19 2.92 ± 7.60 0.077 0.481
Vitamin B2 (mg/d) 1.77 ± 0.98 2.18 ± 0.65 0.41 ± 1.03 0.008 1.59 ± 0.72 2.26 ± 1.04 0.67 ± 1.24 0.006 0.752
Nicotinic acid (mg/
d)
22.5 ± 8.8 25.9 ± 9.3 3.5 ± 12.2 0.217 19.5 ± 8.3 29.3 ± 15.0 9.8 ± 15.0 <0.001 0.159
Vitamin B6 (mg/d) 2.11 ± 0.80 2.52 ± 1.31 0.41 ± 1.17 0.122 1.98 ± 0.89 2.75 ± 1.31 0.77 ± 1.44 0.002 0.296
Folic acid (μg/d) 250.4 ± 157.3 354.1 ± 88.9 103.7 ± 119.1 0.001 239.5 ± 82.7 371.5 ± 139.4 131.9 ± 153.3 <0.001 0.716
Vitamin B12 (μg/d) 11.14 ± 15.76 10.54 ± 4.74 -0.61 ± 16.15 0.063 8.65 ± 7.70 10.83 ± 5.19 2.18 ± 9.35 0.050 0.369
Vitamin C (mg/d) 92.8 ± 89.2 79.2 ± 29.6 -13.6 ± 86.0 0.848 88.9 ± 40.6 92.3 ± 48.5 3.4 ± 64.1 0.758 0.771
Sodium (g/d) 3.14 ± 1.23 3.02 ± 1.24 -0.12 ± 1.10 0.715 3.39 ± 1.87 3.50 ± 2.21 0.11 ± 2.54 0.485 0.716
Chloride (g/d) 4.74 ± 1.71 4.62 ± 1.84 -0.12 ± 1.51 0.741 5.03 ± 2.65 5.29 ± 3.38 0.26 ± 3.86 0.592 0.644
Salt (g/d) 7.1 ± 2.7 6.9 ± 2.8 -0.2 ± 2.4 0.715 7.5 ± 4.2 7.8 ± 5.1 0.4 ± 5.9 0.509 0.789
Fiber (g/d) 21.9 ± 11.7 22.2 ± 7.2 0.32 ± 8.96 0.434 24.1 ± 10.5 25.3 ± 13.4 1.16 ± 14.47 0.910 0.808
Purins (mg/d) 203.9 ± 67.0 201.9 ± 98.8 -2.0 ± 111.8 0.821 200.7 ± 98.6 230.1 ± 129.3 27.0 ± 145.5 0.327 0.464
Uric acid (mg/d) 613.4 ± 201.4 605.9 ± 297.7 -7.5 ± 336.1 0.794 586.3 ± 279.8 685.2 ± 352.7 98.9 ± 397.4 0.072 0.224
1 data are presented as mean ± SD
a p values for comparison between week 0 and 12 (Wilcoxon-Test)
b p values for comparison of group × time interactions (Mann-Whitney-U-Test)
2 abbreviations used: ALA, alpha-linolenic acid; DHA, docosahexaenoic acid; EN, energy; EPA, eicosapentaenoic acid; LA, linoleic acid; MCT, medium-chain
triacylglycerols; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; RE, retinol equivalent; SAFA, saturated fatty acids
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Page 5 of 8Since some evidence also pointed at a beneficial effect
on satiety [24], it has been proposed that under free liv-
ing conditions an increase in dietary MCT may result in
less energy intake and contributes to weight manage-
ment. However, the fact that we did not find any
decrease in energy intake and no change in body weight
suggests that the observed effect on WC may be rather
ascribed to an effect on energy expenditure and thermo-
genesis than to an increase in satiety [13,25,26].
Since long-chain PUFA are proposed to reduce TG,
we hypothesized that the intervention may involve an
improvement in dyslipidemia. However, in our study the
consumption of the fat spreads did not result in any
reductions in blood lipids. In contrast, we observed a
significant rise in fasting TG in both groups after sup-
plementation. It is suggested that fasting TG may have
been affected by changes in dietary habits regarding the
quantity and quality of fat intake. Fatty acid intake pro-
file of patients revealed a rise in the intake from MUFA,
especially oleic acid, in both groups. Table 4 shows that
TG-lowering effect could be attributed only to MCT
intake, whereas MUFA increased serum TG.
This rise in fat consumption may have counteracted
any beneficial effects of the n-3-PUFA and may have
caused the adverse effect on fasting TG instead. It
further indicates that the spreadable fat has not fully
been consumed as a replacement of other fat in the diet
as intended, but rather in addition. In deed, several
patients reported that the consumption of 30 g/d of
spread during the study was much higher than the
amount of spread they usually consume which was
reflected in their dietary protocols. However, observa-
tions in free-living conditions illustrated that users of
plant sterol enriched margarines generally consumed
less than the 20 g/d recommended by the manufac-
turers. The average daily intake of phytosterol-enriched
margarine ranged between 9 and 14 g [27], indicating
that the serving size chosen in this study may not be
consistent with habitual spread intake in Europe. Unpre-
dictable effects such as changes in physical activity and
nutritional behaviour over time which are difficult to
control for may bias results even in carefully designed
studies [28].
An additional effect on fasting TG may have been
expected due to n-3-PUFA supplementation with the fat
spreads. With combined daily intake of 240 mg DHA +
EPA and 870/900 mg ALA, the n-3-PUFA intake may
have been too low to produce a triglyceride-lowering
effect. The recommended daily intake of n-3-PUFA for
the treatment of hypertriglyceridemia is 2 to 4 g [15].
The consumption of the fat spreads did not adversely
affect fasting glucose, insulin, HOMA index, HbA1c,
ASAT or ALAT. As GGT increased in MCT ≤ 7 group,
no general effect of MCT supplementation on GGT
could be derived.
The observed reduction in urinary pH in the MCT > 7
group may be referred to the fact that MCT have a
ketogenic character, as acetyl-CoA produced during
medium-chain fatty acid oxidation is directed towards
ketone body production [10]. Additionally, oral adminis-
tration of MCT leads to urinary elimination of C6, C8
and C10 dicarboxylic acid [29,30].
Except for the MCT intake, no significant differences
in macro- and micronutrient consumption were
observed between both groups. Therefore, it is unlikely
that the observed reduction in WC could be related to
other nutritional factors than the MCT intake. It is sug-
gested that the micronutrient intake with the fat spread
was too low to achieve further beneficial cardio-meta-
bolic effects.
In summary, a daily intake of at least 7 g MCT benefi-
cially affects visceral fat mass, objectivised as WC, in
overweight diabetic patients. As the daily intake of MCT
through the normal diet is relatively small, a moderate
enrichment of food with MCT may effectively contri-
bute to achieve this required intake. The supply of MCT
through enriched fat spreads may be adequate for indi-
viduals who are used to consume a high amount of
spread on a daily basis. But, it may be reasonable to
reassess the suitability of a fat spread as matrix for
MCT. As dietary counselling for diabetic patients
includes recommendations to reduce and modify the fat
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p = 0.471 p = 0.881 p = 0.930 p = 0.842 p = 0.141 p = 0.962 p = 0.987 p = 0.163
*without oleic acid
**without MCT
1 abbreviations used: MCT, medium-chain triacylglycerols; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; SAFA, saturated fatty acids
2 gender is coded by 1 (women) and 2 (men)
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Page 6 of 8intake, alternative food matrices such as oil and milk
products may be interesting alternatives in order to
ensure a healthy overall diet. Since no significant differ-
ences in macro- and micronutrient consumption were
observed between both groups, it is suggested that any
beneficial effects of the n-3-PUFA and vitamins may
have been counteracted by the increased intake of other
fatty acids.
Additional material
Additional file 1: Trial profile
1. The trial profile shows flow of the
patients from screening to study completion.
1 abbreviations used: ITT,
intention to treat, MCT, medium-chain triacylglycerols; PP, per protocol
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